Innovative immuno-therapeutics with first-in-class efficacy and durability to treat tumors with low immunogenicity
Attivare Therapeutics was established by a team from the Wyss Institute at Harvard to address the challenge of treating tumors with low immunogenicity. We are developing an off-the-shelf solution that generates a personalized immune response targeting the patient’s own tumor antigens. They are doing this by advancing the development of the AttImmune platform based on their biomaterial scaffold that can recruit, reprogram, and release target immune cells. The AttImmune platform provides 3D spatiotemporal control of bioactive components, which substantially increases both the magnitude and durability of patient immune responses. In addition, our platform synergizes with standard of care and has applications beyond oncology including the treatment of infectious diseases.